Dumoulin G, Hory B, Nguyen N U, Henriet M T, Bresson C, Bittard H, Saint-Hillier Y, Regnard J
Explorations Fonctionnelles Rénales Métaboliques, Centre Hospitalier Universitaire, Besançon, France.
Kidney Int. 1997 Mar;51(3):804-10. doi: 10.1038/ki.1997.113.
Nephrolithiasis is uncommon after kidney transplantation. However, calcium (Ca) supplementation, which has been proposed as a treatment of post-transplant osteopenia, might increase calciuria and bolster Ca stone formation. Therefore, in 24-hour urine of 82 normocalcemic long-term renal transplant recipients (RT) and in 82 healthy subjects (HS), we assessed some Ca nephrolithiasis risk factors and the Ca-salt saturation estimated by the ion-activity product index (AP) and relative supersaturation (RS). In RT, calciuria was lower (mean +/- SD, 3.20 +/- 2.25 vs. 4.61 +/- 1.71 mmol/day; P < 0.001), urinary volume higher (2.41 +/- 0.83 vs. 1.39 +/- 0.53 liter/day; P < 0.001), oxaluria higher (419 +/- 191 vs. 311 +/- 79 mumol/day; P < 0.001) and citraturia lower (1.40 +/- 1.36 vs. 3.77 +/- 1.36 mmol/day; P < 0.001) than in HS. As a result, Ca-oxalate supersaturation was lower in RT than HS (AP, 1.07 +/- 0.69 vs. 2.07 +/- 1.13, P < 0.001; and RS, 0.62 +/- 0.26 vs. 0.94 +/- 0.21, P < 0.001), and was similar in subgroups of RT (N = 37) and HS (N = 37) matched for urinary volume, demonstrating that even without any larger urinary volume, Ca-oxalate saturation was not higher in RT than HS, and suggesting that opposite changes in Ca and oxalate in RT likely canceled their effects on lithogenic risk. In RT which had similar urinary pH and phosphate (P) than HS, Ca-P supersaturation was lower than in HS for brushite (AP, 3.25 +/- 6.67 vs. 6.01 +/- 4.85, P < 0.001; RS, -0.33 +/- 0.76 vs. 0.48 +/- 0.53, P < 0.001) and octacalcium phosphate (RS, -0.95 +/- 0.72 vs. 0.21 +/- 0.85, P < 0.001), and similar for apatite. Finally, fasting calciuria and calciuric response to a single oral Ca load were similar in RT (N = 19) and HS (N = 8). Together, these results argue strongly against a higher risk of Ca stone formation in RT than HS, even in case of Ca supplementation.
肾结石在肾移植后并不常见。然而,钙补充剂被提议用于治疗移植后骨质减少,但可能会增加尿钙排泄并促进钙结石形成。因此,我们对82名血钙正常的长期肾移植受者(RT)和82名健康受试者(HS)的24小时尿液进行了检测,评估了一些钙肾结石的危险因素以及通过离子活度积指数(AP)和相对过饱和度(RS)估算的钙盐饱和度。在RT中,尿钙排泄较低(均值±标准差,3.20±2.25 vs. 4.61±1.71 mmol/天;P<0.001),尿量较高(2.41±0.83 vs. 1.39±0.53升/天;P<0.001),草酸尿较高(419±191 vs. 311±79 μmol/天;P<0.001),枸橼酸尿较低(1.40±1.36 vs. 3.77±1.36 mmol/天;P<0.001),均低于HS。结果,RT中草酸钙过饱和度低于HS(AP,1.07±0.69 vs. 2.07±1.13,P<0.001;RS,0.62±0.26 vs. 0.94±0.21,P<0.001),并且在RT(N = 37)和HS(N = 37)中按尿量匹配的亚组中相似,表明即使没有更大的尿量,RT中草酸钙饱和度也不高于HS,这表明RT中钙和草酸的相反变化可能抵消了它们对结石形成风险的影响。在尿pH值和磷酸盐(P)与HS相似的RT中,对于透钙磷石,RT中钙磷过饱和度低于HS(AP,3.25±6.67 vs. 6.01±4.85,P<0.001;RS,-0.33±0.76 vs. 0.48±0.53,P<0.001),对于磷酸八钙也是如此(RS,-0.95±0.72 vs. 0.21±0.85,P<0.001),而对于磷灰石则相似。最后,RT(N = 19)和HS(N = 8)的空腹尿钙排泄和对单次口服钙负荷的尿钙反应相似。总之,这些结果有力地反驳了RT比HS有更高的钙结石形成风险这一观点,即使在补充钙的情况下也是如此。